{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:15:22Z","timestamp":1791450922047,"version":"4.3.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82270175"],"award-info":[{"award-number":["82270175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Foundation of Fujian Province of China","award":["2021J02040"],"award-info":[{"award-number":["2021J02040"]}]},{"name":"Joint Funds for the Innovation of Science and Technology of Fujian Province","award":["2023Y9173"],"award-info":[{"award-number":["2023Y9173"]}]},{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program","doi-asserted-by":"crossref","award":["2021-76"],"award-info":[{"award-number":["2021-76"]}],"id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fujian Provincial Clinical Research Center for Hematological Malignancies","award":["2020Y2006"],"award-info":[{"award-number":["2020Y2006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-84047-2","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T11:58:16Z","timestamp":1736251096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"given":"Kaili","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zezhong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renyao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4326-8552","authenticated-orcid":false,"given":"Wenjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-3990","authenticated-orcid":false,"given":"Zhenshu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"issue":"5","key":"84047_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"A Cowan","year":"2022","unstructured":"Cowan, A. et al. Diagnosis and management of multiple myeloma: a review. JAMA 327(5), 464\u2013477. https:\/\/doi.org\/10.1001\/jama.2022.0003 (2022).","journal-title":"JAMA"},{"issue":"2","key":"84047_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"M Lekha","year":"2020","unstructured":"Lekha, M. & James, N. K. CAR T cell therapies for patients with multiple myeloma. Nat. Rev. Clin. Oncol. 18(2), 71\u201384. https:\/\/doi.org\/10.1038\/s41571-020-0427-6 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10272","key":"84047_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/s0140-6736(21)00135-5","volume":"397","author":"WCJ Niels","year":"2021","unstructured":"Niels, W. C. J., vdD, Charlotte, P. & Kwee, L. Y. Multiple myeloma. Lancet 397(10272), 410\u2013427. https:\/\/doi.org\/10.1016\/s0140-6736(21)00135-5 (2021).","journal-title":"Lancet"},{"issue":"1","key":"84047_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0807-5","volume":"12","author":"L Jiangmei","year":"2019","unstructured":"Jiangmei, L. et al. Incidence and mortality of multiple myeloma in China, 2006\u20132016: an analysis of the global burden of Disease Study 2016. J. Hematol. Oncol. 12(1), 1\u20137. https:\/\/doi.org\/10.1186\/s13045-019-0807-5 (2019).","journal-title":"J. Hematol. Oncol."},{"issue":"10218","key":"84047_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/s0140-6736(19)32956-3","volume":"395","author":"M Maria-Victoria","year":"2019","unstructured":"Maria-Victoria, M. et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 395(10218), 132\u2013141. https:\/\/doi.org\/10.1016\/s0140-6736(19)32956-3 (2019).","journal-title":"Lancet"},{"key":"84047_CR6","doi-asserted-by":"publisher","first-page":"649824","DOI":"10.3389\/fmed.2021.649824","volume":"8","author":"Q Ying","year":"2021","unstructured":"Ying, Q. et al. Successful treatment of Relapsed\/Refractory Extramedullary multiple myeloma with Anti-BCMA CAR-T cell therapy followed by Haploidentical hematopoietic stem cell transplantation: a Case Report and a review of the contemporary literature. Front. Med. (Lausanne). 8, 649824. https:\/\/doi.org\/10.3389\/fmed.2021.649824 (2021).","journal-title":"Front. Med. (Lausanne)"},{"issue":"3","key":"84047_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","volume":"4","author":"D Binod","year":"2018","unstructured":"Binod, D. et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of Novel Agent induction: a systematic review and Meta-analysis. JAMA Oncol. 4(3), 343\u2013350. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4600 (2018).","journal-title":"JAMA Oncol."},{"issue":"4","key":"84047_CR8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/bjh.14394","volume":"180","author":"E Felicity","year":"2016","unstructured":"Felicity, E. et al. A population-based study of the impact of dialysis on mortality in multiple myeloma. Br. J. Haematol. 180(4), 588\u2013591. https:\/\/doi.org\/10.1111\/bjh.14394 (2016).","journal-title":"Br. J. Haematol."},{"issue":"6","key":"84047_CR9","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"AK Robert","year":"2008","unstructured":"Robert, A. K., Vincent, S. & R Multiple myeloma. Blood 111(6), 2962\u20132972. https:\/\/doi.org\/10.1182\/blood-2007-10-078022 (2008).","journal-title":"Blood"},{"issue":"8","key":"84047_CR10","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"K Shaji","year":"2016","unstructured":"Shaji, K. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17(8), e328\u2013e346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6 (2016).","journal-title":"Lancet Oncol."},{"issue":"6","key":"84047_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1365-2141.2004.04984.x","volume":"125","author":"R Brown","year":"2004","unstructured":"Brown, R. et al. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br. J. Haematol. 125(6), 743\u2013748 (2004).","journal-title":"Br. J. Haematol."},{"issue":"2","key":"84047_CR12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3324\/haematol.2011.050138","volume":"97","author":"FP Luis","year":"2011","unstructured":"Luis, F. P. et al. Peripheral blood lymphocyte\/monocyte ratio at diagnosis and survival in classical Hodgkin\u2019s lymphoma. Haematologica 97 (2), 262. https:\/\/doi.org\/10.3324\/haematol.2011.050138 (2011).","journal-title":"Haematologica"},{"key":"84047_CR13","doi-asserted-by":"publisher","unstructured":"M M P, L. S., K H B, A A-K, M R L, C A H, R P K, L F P, A. P. & N G, A T Prognostic relevance of Lymphocytopenia, Monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. Blood Cancer J. 7(3), e550. https:\/\/doi.org\/10.1038\/bcj.2017.30 (2017).","DOI":"10.1038\/bcj.2017.30"},{"issue":"3","key":"84047_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","volume":"54","author":"IG Wilson","year":"2018","unstructured":"Wilson, I. G. et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-adapted therapy (mSMART) consensus statement. Bone Marrow Transpl. 54(3), 353\u2013367. https:\/\/doi.org\/10.1038\/s41409-018-0264-8 (2018).","journal-title":"Bone Marrow Transpl."},{"key":"84047_CR15","doi-asserted-by":"publisher","unstructured":"M A D, C, A. M. P. H. R. F. M. F. J. H. J. B. N. C. L. C. et al. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow Transpl. 52(12), 1616\u20131622. https:\/\/doi.org\/10.1038\/bmt.2017.198 (2017).","DOI":"10.1038\/bmt.2017.198"},{"key":"84047_CR16","doi-asserted-by":"publisher","unstructured":"Karine, A-M. et al. R\u00e9gis Peffault dL, J\u00e9r\u00f4me C Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC. Bone Marrow Transplant 53 (6):749\u2013755. https:\/\/doi.org\/10.1038\/s41409-018-0122-8 (2018).","DOI":"10.1038\/s41409-018-0122-8"},{"issue":"1","key":"84047_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1517\/14656566.2014.852537","volume":"15","author":"L Franco","year":"2013","unstructured":"Franco, L., Barbarella, L. & Pietro, M. Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opin. Pharmacother. 15 (1), 23\u201336. https:\/\/doi.org\/10.1517\/14656566.2014.852537 (2013).","journal-title":"Expert Opin. Pharmacother"},{"issue":"3","key":"84047_CR18","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3109\/10428194.2014.930849","volume":"56","author":"F Christelle","year":"2014","unstructured":"Christelle, F. et al. Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leuk. Lymphoma 56(3), 656\u2013662. https:\/\/doi.org\/10.3109\/10428194.2014.930849 (2014).","journal-title":"Leuk. Lymphoma"},{"key":"84047_CR19","doi-asserted-by":"publisher","unstructured":"M, R. O., D M B, R. M. S., B-M S, J. M. & O R Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transpl. 48 (4), 537\u2013543. https:\/\/doi.org\/10.1038\/bmt.2012.239 (2012).","DOI":"10.1038\/bmt.2012.239"},{"issue":"12","key":"84047_CR20","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00277-013-1847-5","volume":"92","author":"L Ho Sup","year":"2013","unstructured":"Ho Sup, L. et al. Predictive factors for rapid neutrophil and platelet engraftment after allogenic peripheral blood stem cell transplantation in patients with acute leukemia. Ann. Hematol. 92(12), 1685\u20131693. https:\/\/doi.org\/10.1007\/s00277-013-1847-5 (2013).","journal-title":"Ann. Hematol."},{"key":"84047_CR21","doi-asserted-by":"publisher","unstructured":"A M K, N E-S, H K M, M-R K, A, E. H., Abd, O. F. R. & EF, D S Impact of CD34 subsets on engraftment kinetics in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transpl. 35 (2), 129\u2013136. https:\/\/doi.org\/10.1038\/sj.bmt.1704755 (2004).","DOI":"10.1038\/sj.bmt.1704755"},{"key":"84047_CR22","doi-asserted-by":"publisher","unstructured":"S Q F, C N A, J K B, J J I, D N, J. L. L. Impact of mobilized blood progenitor cell quality determined by the CFU-GM\/CD34\u2009+\u2009ratio on rapid engraftment after blood stem cell transplantation. Blood Cells Mol. Dis. 28(3), 315\u2013321. https:\/\/doi.org\/10.1006\/bcmd.2002.0519 (2002).","DOI":"10.1006\/bcmd.2002.0519"},{"issue":"1","key":"84047_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.transci.2006.08.009","volume":"36","author":"E Ulk\u00fc","year":"2007","unstructured":"Ulk\u00fc, E., Se\u00e7kin, C., Mustafa, P., M\u00fcmtaz, Y. & Murat, T. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT). Transfus. Apher Sci. 36(1), 23\u201329. https:\/\/doi.org\/10.1016\/j.transci.2006.08.009 (2007).","journal-title":"Transfus. Apher Sci."},{"issue":"2","key":"84047_CR24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4161\/oxim.2.2.8355","volume":"2","author":"LG Thissiane","year":"2010","unstructured":"Thissiane, L. G., Dalila, M. B. & Gabriela, B. Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation. Oxid. Med. Cell. Longev. 2(2), 82\u201387. https:\/\/doi.org\/10.4161\/oxim.2.2.8355 (2010).","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"3","key":"84047_CR25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2141.2006.06019.x","volume":"133","author":"S Ramaprasad","year":"2006","unstructured":"Ramaprasad, S. et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br. J. Haematol. 133(3), 305\u2013314. https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06019.x (2006).","journal-title":"Br. J. Haematol."},{"key":"84047_CR26","doi-asserted-by":"publisher","unstructured":"T U, K. T., H, H. Y. Y. E. H. Y., K, H. T. M. A. M. R. T. K. K. M. I. & Y, T N Expansion of human NOD\/SCID-repopulating cells by stem cell factor, Flk2\/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor. J. Clin. Invest. 105(7), 1013\u20131021. https:\/\/doi.org\/10.1172\/jci8583 (2000).","DOI":"10.1172\/jci8583"},{"key":"84047_CR27","doi-asserted-by":"crossref","unstructured":"G, T., S, S. J. D. V. J. N. & T, L M, B C, J C, B B Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 85(2), 588\u2013596 (1995).","DOI":"10.1182\/blood.V85.2.588.bloodjournal852588"},{"key":"84047_CR28","doi-asserted-by":"publisher","unstructured":"W B, F A, S R, R S, J S, K L, T G, T D, K S, C W Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J. Clin. Oncol. 13(10): 2547\u20132455. (1995). https:\/\/doi.org\/10.1200\/jco.1995.13.10.2547","DOI":"10.1200\/jco.1995.13.10.2547"},{"issue":"13","key":"84047_CR29","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1182\/blood-2009-03-208355","volume":"114","author":"AP Michael","year":"2009","unstructured":"Michael, A. P. et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34\u2009+\u2009cell dose. Blood 114(13), 2606\u20132616. https:\/\/doi.org\/10.1182\/blood-2009-03-208355 (2009).","journal-title":"Blood"},{"key":"84047_CR30","doi-asserted-by":"publisher","first-page":"736137","DOI":"10.3389\/fimmu.2021.736137","volume":"12","author":"H Clarissa","year":"2021","unstructured":"Clarissa, H. et al. CD4\u2009+\u2009T cell dependent B cell recovery and function after autologous hematopoietic stem cell transplantation. Front. Immunol. 12, 736137. https:\/\/doi.org\/10.3389\/fimmu.2021.736137 (2021).","journal-title":"Front. Immunol."},{"issue":"3","key":"84047_CR31","doi-asserted-by":"publisher","first-page":"328","DOI":"10.24272\/j.issn.2095-8137.2020.038","volume":"41","author":"Y Yang","year":"2020","unstructured":"Yang, Y. et al. Whole-genome sequencing of leopard coral grouper (Plectropomus leopardus) and exploration of regulation mechanism of skin color and adaptive evolution. Zool. Res. 41(3), 328\u2013340. https:\/\/doi.org\/10.24272\/j.issn.2095-8137.2020.038 (2020).","journal-title":"Zool. Res."},{"issue":"1","key":"84047_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40364-021-00309-5","volume":"9","author":"Y Zixun","year":"2021","unstructured":"Zixun, Y., Ya, Z. & Xin, W. Advances in chimeric antigen receptor T-cell therapy for B-cell non-hodgkin lymphoma. Biomark. Res. 9(1), 58. https:\/\/doi.org\/10.1186\/s40364-021-00309-5 (2021).","journal-title":"Biomark. Res."},{"issue":"3","key":"84047_CR33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000069285","volume":"109","author":"H Melinda","year":"2003","unstructured":"Melinda, H. et al. Homogeneous immunoglobulins following allogeneic bone marrow transplantation. Acta Haematol. 109(3), 124\u2013128. https:\/\/doi.org\/10.1159\/000069285 (2003).","journal-title":"Acta Haematol."},{"issue":"3","key":"84047_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/sj.bmt.1705892","volume":"41","author":"DS A-C N","year":"2007","unstructured":"A-C N, D. S., O, J. M. P. L. & R, M R Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transpl. 41(3), 267\u2013273. https:\/\/doi.org\/10.1038\/sj.bmt.1705892 (2007).","journal-title":"Bone Marrow Transpl."},{"issue":"5","key":"84047_CR35","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/pbc.25409","volume":"62","author":"S Mikael","year":"2015","unstructured":"Mikael, S. et al. Hypogammaglobulinemia in children after allogeneic hematopoietic stem cell transplantation: a cytokine mediated immunoglobulin isotype class switch arrest? Pediatr. Blood Cancer. 62(5), 890\u2013896. https:\/\/doi.org\/10.1002\/pbc.25409 (2015).","journal-title":"Pediatr. Blood Cancer"},{"key":"84047_CR36","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","volume":"139","author":"EP Elena","year":"2017","unstructured":"Elena, E. P. et al. Update on the use of immunoglobulin in human disease: a review of evidence. J. Allergy Clin. Immunol. 139, S1\u2013S46. https:\/\/doi.org\/10.1016\/j.jaci.2016.09.023 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8","key":"84047_CR37","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1080\/10428194.2017.1403026","volume":"59","author":"V Jimenez-Zepeda","year":"2018","unstructured":"Jimenez-Zepeda, V. et al. Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. Leuk. Lymphoma 59(8), 1920\u20131926. https:\/\/doi.org\/10.1080\/10428194.2017.1403026 (2018).","journal-title":"Leuk. Lymphoma"},{"issue":"0","key":"84047_CR38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00651.x","volume":"224","author":"M Alessandro","year":"2008","unstructured":"Alessandro, M., Franco, L. & Lorenzo, M. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Immunol. Rev. 224(0), 58\u201369. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00651.x (2008).","journal-title":"Immunol. Rev."},{"issue":"5","key":"84047_CR39","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.smim.2007.10.001","volume":"19","author":"N Legrand","year":"2007","unstructured":"Legrand, N., Dontje, W., van Lent, A., Spits, H. & Blom, B. Human thymus regeneration and T cell reconstitution. Semin. Immunol. 19(5), 280\u2013288. https:\/\/doi.org\/10.1016\/j.smim.2007.10.001 (2007).","journal-title":"Semin. Immunol."},{"issue":"5","key":"84047_CR40","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood-2007-03-079160","volume":"110","author":"S Mielke","year":"2007","unstructured":"Mielke, S. et al. Reconstitution of FOXP3\u2009+\u2009regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood 110(5), 1689\u20131697. https:\/\/doi.org\/10.1182\/blood-2007-03-079160 (2007).","journal-title":"Blood"},{"issue":"3","key":"84047_CR41","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.bbmt.2007.12.490","volume":"14","author":"B Michael","year":"2008","unstructured":"Michael, B. et al. Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. Biol. Blood Marrow Transpl. 14(3), 290\u2013300. https:\/\/doi.org\/10.1016\/j.bbmt.2007.12.490 (2008).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"84047_CR42","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3389\/fimmu.2020.01413","volume":"11","author":"J Vald\u00e9s-Ferrada","year":"2020","unstructured":"Vald\u00e9s-Ferrada, J. et al. Peripheral blood classical monocytes and plasma interleukin 10 are Associated to Neoadjuvant Chemotherapy response in breast Cancer patients. Front. Immunol. 11, 1413. https:\/\/doi.org\/10.3389\/fimmu.2020.01413 (2020).","journal-title":"Front. Immunol."},{"issue":"13","key":"84047_CR43","doi-asserted-by":"publisher","first-page":"14207","DOI":"10.1002\/cam4.6088","volume":"12","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Prognostic nutritional index combined with NLR to construct a survival prediction model and decision analysis of patients with muscle-invasive bladder cancer after surgery. Cancer Med. 12(13), 14207\u201314224. https:\/\/doi.org\/10.1002\/cam4.6088 (2023).","journal-title":"Cancer Med."},{"issue":"14","key":"84047_CR44","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.12998\/wjcc.v10.i14.4380","volume":"10","author":"Z Xu","year":"2022","unstructured":"Xu, Z., Yao, X., Shi, X. & Du, X. Significance of preoperative peripheral blood neutrophil-lymphocyte ratio in predicting postoperative survival in patients with multiple myeloma bone disease. World J. Clin. Cases. 10(14), 4380\u20134394. https:\/\/doi.org\/10.12998\/wjcc.v10.i14.4380 (2022).","journal-title":"World J. Clin. Cases"},{"key":"84047_CR45","doi-asserted-by":"publisher","first-page":"670673","DOI":"10.3389\/fonc.2021.670673","volume":"11","author":"Y Yang","year":"2021","unstructured":"Yang, Y., Liu, Z., Wang, H. & Zhang, G. HLA-E binding peptide as a potential therapeutic candidate for high-risk multiple myeloma. Front. Oncol. 11, 670673. https:\/\/doi.org\/10.3389\/fonc.2021.670673 (2021).","journal-title":"Front. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84047-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84047-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84047-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T12:14:03Z","timestamp":1736252043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84047-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84047"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84047-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"21 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by Ethical Committee of Fujian Medical University Union Hospital and informed consent was obtained from each participant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"1222"}}